Catalogue exports from research-peptide suppliers carry a dense layer of storage and diluent vocabulary that is rarely reviewed on its own terms. The present dataset contains peptide storage container, peptide storage containers, peptide storage cases, peptides storage box, peptide box, peptides case, peptide vial cases, peptide holders and peptides container on the container side; bacteriostatic water - 10ml, 10ml bac water, 10 ml bac water, bac water 10 ml, 5ml bac water, bac water 5ml, 5ml bacteriostatic water, bacteriostatic water for injection 30ml, 30ml bacteriostatic water, bac water 30 ml, 30 ml bac water and bacteriostatic water 30 ml on the diluent side; and fill-mass labels such as epithalon 10mg, bpc 157 5 mg, 5-amino-1mq 50mg vial and nad 500mg vial on the product side. This review treats those strings as nomenclature for a container closure system, a diluent fill volume and a lyophilised fill mass, and reads them against the peer-reviewed stability literature. It describes mechanisms and published findings only; every compound named is a research reagent.
Key Facts at a Glance
- A lyophilised peptide's stability is a property of the whole container closure system — cake, residual moisture, headspace, glass and stopper — not of the sequence alone [2][3].
- Solid-state degradation is governed by residual water and the glass-transition temperature of the cake; below Tg molecular mobility, and therefore chemical degradation, is strongly suppressed [4].
- Freeze–thaw damage arises from freeze-concentration, ice-surface adsorption and pH shifts, and its magnitude depends on cooling and warming rates [9][10].
- Peptides adsorb measurably to polypropylene and untreated glass; recovery differences between labware types can exceed the analytical variance of the assay [11].
- Bacteriostatic water is water for injection preserved with 0.9 % benzyl alcohol; the 5 ml, 10 ml and 30 ml labels are fill volumes of the diluent vial, not properties of the peptide [15].
Definition. A container closure system is the sum of packaging components that together contain and protect a dosage form: the primary container (vial), the closure (elastomeric stopper), the seal and any secondary packaging. In the research-peptide catalogue, the strings peptide storage container, peptide vial cases and peptide holders refer to secondary containment — boxes, racks and cases that hold sealed vials — and not to the primary vial itself.
1. Why the Container Is Part of the Formulation
Freeze-drying converts a peptide solution into a porous solid by freezing, primary drying (ice sublimation) and secondary drying (desorption of unfrozen water). Wang's review explains the purpose: removing water slows hydrolytic and many oxidative reactions and restricts conformational mobility [2]. The product is not the peptide alone but a cake whose residual moisture, specific surface area and excipient glass determine subsequent stability [2].
Carpenter and colleagues' practical guidance on lyophilised formulations makes the container explicit. Vial geometry sets the fill depth and therefore the drying time; the stopper's moisture content can re-humidify a dry cake during storage; and headspace gas composition affects oxidation [3]. Chang and Pikal's mechanistic review adds the governing variable: the glass-transition temperature (Tg) of the amorphous cake. Above Tg the matrix behaves as a viscous liquid in which degradation proceeds; below it, molecular mobility — and with it deamidation, aggregation and oxidation — is strongly suppressed, though coupling between fast local motions and degradation means that storage below Tg is necessary but not always sufficient [4]. Residual water lowers Tg, which is why a stopper that releases moisture into the vial can move a cake from the glassy into the rubbery state without any change in nominal storage temperature [3][4].
Roy and Gupta catalogue the stresses that survive freeze-drying — cold denaturation, ice-interface adsorption, buffer-crystallisation pH shift and dehydration of the hydration shell [5] — each a property of process and container rather than of the compound label. The strings peptides vial, bpc 157 vials and slu pp 332 vial therefore describe a Type I glass container whose stability history began before the vial was sealed.
2. Degradation Pathways as a Function of Temperature and Water
Manning and colleagues' 2010 update on protein pharmaceutical stability separates physical instability (unfolding, aggregation, surface adsorption, precipitation) from chemical instability (deamidation, isomerisation, oxidation, hydrolysis, disulfide scrambling, β-elimination) [1]. Both classes are temperature-dependent and both are modulated by water activity, which is why the same peptide carries different shelf-life classes as a lyophilised solid, a frozen solution and a refrigerated solution [1][2].
2.1 Deamidation and isomerisation
Asparagine and glutamine deamidation proceeds through a succinimide intermediate whose rate depends on sequence context, pH and temperature. Robinson and Robinson compiled first-order deamidation half-times for asparaginyl residues in defined peptides and showed that they range over orders of magnitude with the identity of the following residue — Asn-Gly being fastest — and that the reaction functions as a 'molecular clock' in proteins [6]. Below Tg in a dry cake the clock runs slowly; in ambient solution it runs at its solution rate, for some Asn-Gly motifs measured in days [6].
2.2 Oxidation
Li, Schöneich and Borchardt reviewed the oxidation chemistry of methionine, cysteine, histidine, tryptophan and tyrosine in protein pharmaceuticals, identifying dissolved oxygen, trace transition metals, peroxide impurities in excipients and light as the principal drivers [7]. Two container variables follow directly: headspace oxygen and the metal content of glass [7].
2.3 Photodegradation
Kerwin and Remmele's review 'Protect from light' documents that ultraviolet and visible light drive tryptophan, tyrosine, histidine and methionine oxidation via photosensitised singlet oxygen and direct photolysis, and that clear glass transmits most of the relevant spectrum [8]. The catalogue strings peptide storage cases, peptides storage box and peptide box map onto exactly the secondary packaging function these authors describe: opaque containment that limits cumulative light exposure of clear vials [8].
2.4 Arrhenius behaviour and accelerated ageing
Waterman and Adami's review of accelerated ageing shows that for many solid pharmaceuticals degradation rate follows a modified Arrhenius relationship in which both temperature and relative humidity appear as independent variables, allowing shelf life at one condition to be predicted from short studies at higher temperature and humidity [17]. The temperature ladder on this article's cover — ultra-low, frozen, refrigerated, ambient, excursion — therefore maps onto distinct degradation-rate classes, and humidity ingress through a closure is as consequential as a thermal excursion [17].
3. Freezing, Freeze–Thaw and Closure Integrity at Low Temperature
Frozen solution storage is not degradation-free. Bhatnagar, Bogner and Pikal dissected the stresses of freezing into cold denaturation, freeze-concentration of solutes (with attendant ionic-strength and pH shifts as buffers crystallise) and adsorption at the ice–liquid interface, and reviewed how cryoprotectants such as sucrose act through preferential exclusion and vitrification [10]. Cao and colleagues measured denaturation of model proteins as a function of cooling and thawing rate and found that the extent of damage is rate-dependent, with slow thawing generally more damaging for some proteins because of prolonged exposure to freeze-concentrated liquid [9].
Low temperature also challenges the closure itself. Zuleger and colleagues tested container/closure integrity of vial–stopper combinations at −80 °C and showed that elastomeric stoppers pass through their own glass transition near that temperature, losing elasticity so that some combinations transiently leak during cold storage or on warming — an ingress path for moisture and micro-organisms invisible at ambient temperature [14]. A secondary peptide vial case does nothing for a primary closure that has stiffened below its own Tg; closure selection is the controlling variable [14].
4. Surface Chemistry: Adsorption, Delamination and Silicone Oil
Goebel-Stengel and colleagues quantified recovery of several regulatory peptides — including ghrelin, nesfatin-1 and somatostatin analogues — from polypropylene, polystyrene, glass and low-binding tubes, and found losses of tens of percent within hours for some peptide–surface pairs, with hydrophobic and cationic peptides most affected [11]. Labware is thus an experimental variable to be recorded, not a neutral background [11].
Glass is not inert either. Iacocca and colleagues reviewed the factors — glass composition, forming temperature, terminal sterilisation and formulation pH — that govern delamination of pharmaceutical Type I borosilicate vials, producing visible glass lamellae and dissolved silica in the product [12]. Jones, Kaufmann and Middaugh showed that silicone oil, used as a lubricant on syringes and some stoppers, induces aggregation of several model proteins at the oil–water interface [13].
5. Diluent Vials: Bacteriostatic Water and the 5 / 10 / 30 ml Fill Volumes
Meyer and colleagues' survey of antimicrobial preservatives in parenteral products records benzyl alcohol as the most widely used preservative in multi-dose containers, typically at 0.9 % (v/v) in bacteriostatic water for injection, alongside phenol, m-cresol, chlorobutanol and parabens [15]. The catalogue strings 10ml bac water, 5ml bac water and 30ml bacteriostatic water (with the variants listed in Table 2) all encode the same preserved diluent at three vial fill volumes; the volume is a property of the diluent container, not of any peptide it may later be combined with. The unpreserved counterpart appears as 10 ml sterile water for injection and sterile water for injection 10 ml.
The preservative is not stability-neutral. Thirumangalathu and colleagues showed that benzyl alcohol accelerates aggregation of a model therapeutic protein in a pH- and temperature-dependent manner, and that sucrose partially counteracts the effect by shifting the conformational equilibrium away from aggregation-prone intermediates [16]. The punctuation variant bac water. and the co-purchase phrases bac water and syringes and bacteriostatic water for mixing peptides are catalogue-navigation strings and are recorded as such in Table 2. Superlative queries — best bacteriostatic water for injection, best bacteriostatic water for peptides — cannot be resolved by a literature review and are recorded as Declined. Reconstitution-arithmetic queries such as how much bac water for 10mg peptide, how much bac water to reconstitute peptides 10mg and how much bacteriostatic water for 10 mg bpc 157 request protocol guidance and are likewise Declined.
Related handling chemistry is reviewed in the solvent-chemistry review, the bacteriostatic-water media review and the syringe and needle consumables review.
6. Fill-Mass Nomenclature: What a Milligram Label Denotes
Catalogue strings such as epithalon 10mg, bpc 157 5 mg, cagrilintide 10 mg, igf1-lr3 1mg, motsc 40mg and 5-amino-1mq 50mg vial (full list in Table 2) attach a nominal fill mass to a compound name. The fill mass is a lyophilised-cake mass declared by the vendor; because a cake includes counter-ions (commonly trifluoroacetate or acetate) and residual water, peptide content and cake mass differ [1][2], and cake mass affects stability through specific surface area rather than through any property of the compound [2][3]. Whether the substance is a peptide at all is independent of the label: 5-amino-1mq is a small-molecule NNMT inhibitor and nad 500mg vial denotes a dinucleotide, both reviewed elsewhere on this site (5-amino-1MQ, NAD+ buffered vs unbuffered). Strings that pair a mass with a dosage or price token — ghk cu 100 mg dosage, tesamorelin 10mg price — are Declined.
The orthographic strings box 157 peptide and box157 deserve a note: they are almost certainly predictive-text substitutions of 'bpc 157', in which a three-letter acronym is replaced by a common dictionary word, and are recorded as orthography variants pointing to the BPC-157 stability and handling review. Compound-specific reviews for the fill-mass labels are the epithalon review, the cagrilintide review, the IGF-1 LR3 review, the GHK-Cu review, the MOTS-c review and the SLU-PP-332 review.
7. Cold Chain and Temperature Excursions
Ammann's review of the stability studies needed to define handling and transport conditions for sensitive biological products argues that a labelled storage condition is only meaningful when paired with data on tolerated excursions — how long at what temperature, how many cycles — because real distribution involves loading docks, couriers and bench time [18]. Excursion studies should model the actual shipment profile rather than a single elevated temperature [18]; a peptides container or peptide storage container in a shipment functions as a thermal buffer and light shield whose effect on the cumulative time-temperature integral is measurable but rarely stated [17][18].
8. Evidence Table
| Research Model | Signal Vector | Refs |
|---|---|---|
| Lyophilised protein/peptide cakes | Residual moisture, Tg, excipient glass → storage stability class | [2][3][4] |
| Model Asn-containing peptides (kinetic series) | Deamidation half-time by sequence context; 'molecular clock' behaviour | [6] |
| Protein pharmaceuticals (review) | Met/Cys/His/Trp/Tyr oxidation via O2, metals, peroxides, light | [7] |
| Protein biologics under UV/visible light | Photo-oxidation of aromatic and sulfur residues; opaque secondary packaging rationale | [8] |
| Model proteins, controlled freeze–thaw | Denaturation extent depends on cooling/thawing rate and cycle number | [9][10] |
| Regulatory peptides on PP/PS/glass labware | Adsorptive loss of tens of percent for hydrophobic/cationic peptides | [11] |
| Type I borosilicate vials | Delamination governed by glass chemistry, forming, sterilisation and pH | [12] |
| Model proteins with silicone oil | Interface-induced aggregation | [13] |
| Vial–stopper combinations at −80 °C | Transient closure-integrity loss as elastomer passes its Tg | [14] |
| Multi-dose parenteral diluents | Benzyl alcohol 0.9 % as prevalent preservative; alternatives catalogued | [15] |
| Model therapeutic protein + benzyl alcohol | Preservative-accelerated aggregation, pH/temperature dependent, sucrose-attenuated | [16] |
| Solid pharmaceuticals, accelerated ageing | Humidity-corrected Arrhenius prediction of shelf life | [17] |
| Biological products in distribution | Excursion tolerance must be defined by profile-matched stability studies | [18] |
9. Catalogue Vocabulary Crosswalk
Table 2 records each verbatim string in the dataset, the object it denotes and its research-use-only (RUO) scope status. No vendor is assessed or endorsed.
| Verbatim catalogue strings | Object denoted | Literature anchor | RUO scope status |
|---|---|---|---|
| peptide storage container; peptide storage containers; peptides container | Secondary containment (box/rack) | Container closure system — secondary packaging; light shield; thermal buffer [8][18] | Recorded — terminology |
| peptide storage cases; peptides storage box; peptide box; peptides case; peptide vial cases; peptide holders | Secondary containment (case/holder) | Opaque case or rack holding sealed primary vials [8] | Recorded — terminology |
| peptides vial; bpc 157 vials; slu pp 332 vial | Primary container | Type I glass vial + elastomeric stopper; lyophilised cake [3][12][14] | Recorded — nomenclature |
| bacteriostatic water - 10ml; 10ml bac water; 10 ml bac water; bac water 10 ml | Diluent vial, 10 ml fill | Water for injection + 0.9 % benzyl alcohol [15] | Recorded — nomenclature |
| 5ml bac water; bac water 5ml; 5ml bacteriostatic water | Diluent vial, 5 ml fill | Same preserved diluent, smaller fill volume [15] | Recorded — nomenclature |
| bacteriostatic water for injection 30ml; 30ml bacteriostatic water; bac water 30 ml; 30 ml bac water; bacteriostatic water 30 ml | Diluent vial, 30 ml fill | Same preserved diluent, larger fill volume [15] | Recorded — nomenclature |
| 10 ml sterile water for injection; sterile water for injection 10 ml | Unpreserved diluent, 10 ml fill | Water for injection without preservative [15] | Recorded — nomenclature |
| bac water.; bac water and syringes; bacteriostatic water for mixing peptides | Catalogue navigation | Punctuation variant / co-purchase phrase | Recorded — orthography/navigation |
| epithalon 10mg; epithalon 10 mg; epitalon 10 mg; bpc 157 5 mg; cagrilintide 10 mg; igf1-lr3 1mg; 100 mg ghk cu; 100mg ghk cu; motsc 40mg; slu pp 332 5mg | Lyophilised fill mass | Nominal cake mass; peptide content differs by counter-ion and water [1][2] | Recorded — nomenclature |
| 5 amino 1mq 50mg; 5 amino 1mq 50 mg; 5-amino-1mq 50mg vial; nad 500mg vial | Non-peptide fill mass | Small-molecule / dinucleotide vials; not peptides | Recorded — nomenclature |
| box 157 peptide; box157 | Predictive-text substitution | → BPC-157 (bpc → 'box') | Recorded — orthography |
| best bacteriostatic water for injection; best bacteriostatic water for peptides | Superlative/promotional | Not resolvable by literature review; no vendor assessed or endorsed | Declined — promotional |
| how much bac water for 10mg peptide; how much bac water to reconstitute peptides 10mg; how much bacteriostatic water for 10 mg bpc 157 | Reconstitution arithmetic | Protocol request | Declined — protocol |
| ghk cu 100 mg dosage; tesamorelin 10mg price | Dosage / price | Outside RUO scope | Declined — dosage/price |
10. Where to Source for Research
Lyophilised research peptides and preserved or unpreserved diluent vials are listed for laboratory research by several suppliers, including Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. Availability is noted for research reference only; this review does not assess or endorse any supplier, and the catalogue strings analysed above are treated as vocabulary rather than as product recommendations. Researchers evaluating a source may consult the supplier-evaluation guide and the catalogue-format and quality-verification review.
Frequently Asked Questions
What is a peptide storage container in catalogue vocabulary?
In the strings peptide storage container, peptide storage cases and peptide holders, the object is secondary containment: an opaque box, case or rack that holds sealed primary vials. Its documented functions are light exclusion [8] and thermal buffering during transport [18]; it does not alter the primary closure's behaviour [14].
Why do 5 ml, 10 ml and 30 ml appear with bacteriostatic water?
They are fill volumes of the diluent vial. 10ml bac water, 5ml bac water and 30ml bacteriostatic water all denote water for injection preserved with 0.9 % benzyl alcohol [15]; the volume describes the container, not any peptide.
Does a lyophilised peptide degrade in storage?
Yes, but slowly when the cake is kept below its glass-transition temperature with low residual moisture [2][4]. Deamidation, oxidation and photodegradation continue at rates set by temperature, water activity and light exposure [6][7][8][17].
What does freeze–thaw do to a peptide solution?
Freezing concentrates solutes, shifts pH as buffers crystallise and exposes molecules to the ice interface; damage depends on cooling and thawing rates and on cycle number [9][10]. Elastomeric stoppers can also transiently lose seal integrity near −80 °C [14].
Is 'box 157 peptide' a different compound from BPC-157?
No. box 157 peptide and box157 are predictive-text substitutions of 'bpc 157'. They are recorded as orthography variants and point to the BPC-157 stability review on this site.
Does this review say how much bacteriostatic water to use?
No. Strings such as how much bac water for 10mg peptide request protocol guidance and are recorded as Declined. This article is strictly for research reference; not for human or veterinary use.
Works Cited
- [1] Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- [2] Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. doi:10.1016/s0378-5173(00)00423-3 · PMID 10967427
- [3] Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969-975. doi:10.1023/a:1012180707283 · PMID 9279875
- [4] Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J Pharm Sci. 2009;98(9):2886-2908. doi:10.1002/jps.21825 · PMID 19569054
- [5] Roy I, Gupta MN. Freeze-drying of proteins: some emerging concerns. Biotechnol Appl Biochem. 2004;39(Pt 2):165-177. doi:10.1042/BA20030133 · PMID 15032737
- [6] Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A. 2001;98(3):944-949. doi:10.1073/pnas.98.3.944 · PMID 11158575
- [7] Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511 · PMID 18623513
- [8] Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468-1479. doi:10.1002/jps.20815 · PMID 17230445
- [9] Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol Bioeng. 2003;82(6):684-690. doi:10.1002/bit.10612 · PMID 12673768
- [10] Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505-523. doi:10.1080/10837450701481157 · PMID 17963151
- [11] Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009 · PMID 21315060
- [12] Iacocca RG, Toltl N, Allgeier M, et al. Factors affecting the chemical durability of glass used in the pharmaceutical industry. AAPS PharmSciTech. 2010;11(3):1340-1349. doi:10.1208/s12249-010-9506-9 · PMID 20740334
- [13] Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94(4):918-927. doi:10.1002/jps.20321 · PMID 15736189
- [14] Zuleger B, Werner U, Kort A, Glowienka R, Wehnes E, Duncan D. Container/closure integrity testing and the identification of a suitable vial/stopper combination for low-temperature storage at -80 °C. PDA J Pharm Sci Technol. 2012;66(5):453-465. doi:10.5731/pdajpst.2012.00884 · PMID 23035029
- [15] Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci. 2007;96(12):3155-3167. doi:10.1002/jps.20976 · PMID 17722087
- [16] Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci. 2006;95(7):1480-1497. doi:10.1002/jps.20619 · PMID 16729274
- [17] Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1-2):101-125. doi:10.1016/j.ijpharm.2004.12.013 · PMID 15778049
- [18] Ammann C. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. AAPS PharmSciTech. 2011;12(4):1264-1275. doi:10.1208/s12249-011-9684-0 · PMID 21948319
Research-use-only notice. This article is strictly for research reference; not for human or veterinary use. It describes published stability literature and catalogue vocabulary. It contains no dosing, reconstitution, administration or protocol guidance and makes no health, cosmetic or body-composition claims for any compound.
Browse the full compound index in the Peptide Insider receptor-family taxonomy review.